# Stoke Therapeutics

Stoke Therapeutics is an Asset Manager based in Bedford, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Bedford, United States
- **Region:** North America
- **Address:** Bedford, MA, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** stoketherapeutics.com

## Regulatory record

- **Reports private funds:** No

## About

Stoke Therapeutics is a biotechnology company founded in 2017 in Bedford, Massachusetts. It develops therapies for severe diseases by enhancing protein output from healthy genes using its proprietary TANGO platform. The company targets diseases of the central nervous system and the eye with RNA-based medicines.

## Sectors

- Biotechnology
- Rare Disease

## People

- Edward M. Kaye — Chief Executive Officer
- Adrian R. Krainer — Scientific Co-Founder

## Questions

### How does Stoke's TANGO platform differ from standard antisense approaches?

Most antisense oligonucleotides work by binding to mRNA and blocking translation or promoting degradation. Stoke's TANGO platform does the opposite: it binds to pre-mRNA and increases the production of protein from a functional copy of a gene. The core insight, developed by co-founder Adrian Krainer, exploits naturally occurring non-productive splicing events to boost protein output for haploinsufficiencies — diseases where one gene copy produces too little protein (per the company's scientific publications, 2018-2020).

### Does Stoke Therapeutics have any partnership or funding arrangements beyond equity issuance?

In January 2021, Stoke entered a royalty monetization agreement with RTW Investments, receiving development capital in exchange for a percentage of future zorevunersen royalties. This arrangement allowed Stoke to fund its pipeline without diluting shareholders. The company has also accessed the public equity markets since its 2019 IPO to fund research and development.

### What is the scientific origin of Stoke Therapeutics?

The company's technology originates from the laboratory of Adrian Krainer at Cold Spring Harbor Laboratory. Krainer is a leading authority on RNA splicing and antisense therapeutics, best known for co-developing the antisense drug Spinraza for spinal muscular atrophy. Stoke was founded in 2014 to translate his work on RNA-splicing upregulation into treatments for severe genetic diseases.

### What indications beyond Dravet syndrome is Stoke pursuing?

Stoke's pipeline includes STK-002 for autosomal dominant optic atrophy, a rare inherited condition causing vision loss, which is currently in preclinical or early clinical development. The company's TANGO platform is broadly applicable to haploinsufficiencies, but Stoke has publicly committed to focus near-term resources on its SCN1A-related epilepsy programs.

### How is Stoke Therapeutics financed, given it is not a typical investment fund?

Stoke is a publicly traded biotech company listed on Nasdaq, so it finances its operations through equity offerings, strategic partnerships, and royalty-monetization structures rather than through limited partner commitments. Its investor base includes biotech-focused funds, institutional investors, and the public market. There is no AUM or deployable blind-pool capital in the asset-management sense.

## Related profiles

- [G2 Goldfields](https://altss.com/profile/g2-goldfields-inc)
- [Nuveen Municipal Value Fund](https://altss.com/profile/nuveen-municipal-value-fund-inc)

---

Last updated: 2026-05-30T17:33:33.424Z

Canonical page: https://altss.com/profile/stoke-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology